|
- UZEDY® | Official Patient Site
UZEDY (risperidone) extended-release injectable suspension is a prescription medicine used to treat schizophrenia in adults For more information about UZEDY, see the full Prescribing Information, including Boxed WARNING, or talk to your healthcare provider
- Treatment With UZEDY | UZEDY®
UZEDY (risperidone) extended-release injectable suspension is a prescription medicine used to treat schizophrenia in adults For more information about UZEDY, see the full Prescribing Information, including Boxed WARNING, or talk to your healthcare provider
- RIS-41277 UZEDY® HIGHLIGHTS OF PRESCRIBING INFORMATION Initial U. S . . .
INDICATIONS AND USAGE UZEDY is an atypical antipsychotic indicated for the treatment of schizophrenia in adults (1)
- COMMON SIDE EFFECTS - UZEDY®
Learn about the common side effects of UZEDY® (risperidone) extended-release injectable suspension Please see the full Prescribing Information for UZEDY, including Boxed WARNING
- Clinical Trial Results | UZEDY®
UZEDY was researched in a clinical study that included 542 patients who were treated with either UZEDY or placebo This study was the largest and longest clinical study for a risperidone long-acting injectable (LAI) in schizophrenia to date
- Finding Support | UZEDY®
UZEDY (risperidone) extended-release injectable suspension is a prescription medicine used to treat schizophrenia in adults For more information about UZEDY, see the full Prescribing Information, including Boxed WARNING, or talk to your healthcare provider
- Savings and Resources | UZEDY®
UZEDY is an FDA-approved, long-acting injectable (LAI) form of risperidone used to treat schizophrenia in adults Instead of taking a pill every day to help treat your schizophrenia symptoms, with UZEDY, you get 1 injection every 1 or 2 months
- RELAPSE PREVENTION TREATMENT WITH UZEDY.
RELAPSE LESS RISK OF RELAPSE UZEDY® (risperidone) extended-release injectable suspension significantly reduced the risk of relapse compared with placebo in a clinical study † 93% FEWER SETBACKS With once-monthly UZEDY, after 24 weeks (about 6 months) of treatment, the relapse-free rate of patients was 93% vs 72% for those receiving placebo
|
|
|